HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma.
HYDIN
biomarker
immune checkpoint inhibitors
melanoma
prognosis
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
17 08 2023
17 08 2023
Historique:
received:
08
05
2023
accepted:
10
07
2023
medline:
7
9
2023
pubmed:
18
8
2023
entrez:
18
8
2023
Statut:
ppublish
Résumé
The advent of immune checkpoint inhibitors (ICIs) has altered the outlook for cancer treatment. The estimation of predictive biomarkers could contribute to maximizing the benefits from ICIs treatment. Here, we explored the association between HYDIN mutations (HYDIN-MUT) in melanoma and ICIs efficacy. Clinical data and sequencing data from published studies were utilized to assess the association between HYDIN-MUT and the efficacy of ICIs treatment in melanoma patients. Compared to other tumor types, HYDIN (36.14%) has the highest mutation rate in melanoma patients. In the anti-PD-1 treated cohort (n = 254), the HYDIN-MUT patients had a longer OS after ICIs treatment than the HYDIN wild-type (HYDIN-WT) patients (HR = 0.590 [95% CI, 0.410-0.847], P = 0.004); the objective response rate (ORR) and durable clinical benefit (DCB) were increased in patients with HYDIN-MUT (ORR = 46.25, DCB = 56.00%) compared to patients with HYDIN-WT (ORR = 30.99%, DCB = 42.76%) (ORR: P = 0.019; DCB: P = 0.060). In the anti-CTLA4 treated cohort (n = 174), HYDIN-MUT patients achieved significantly longer OS than HYDIN-WT patients (HR = 0.549 [95% CI, 0.366-0.823], P = 0.003); the proportion of ORR and DCB in HYDIN-MUT patients was significantly higher than that in HYDIN-WT patients (ORR 40.54% vs. 14.42%, P = 0.031; DCB 45.76% vs. 22.22%, P = 0.002). Further gene set enrichment analysis demonstrated that DNA repair and anti-tumor immunity were significantly enhanced in HYDIN-MUT patients. HYDIN mutations are a potential predictive biomarker of ICIs efficacy in melanoma patients.
Sections du résumé
BACKGROUND
The advent of immune checkpoint inhibitors (ICIs) has altered the outlook for cancer treatment. The estimation of predictive biomarkers could contribute to maximizing the benefits from ICIs treatment. Here, we explored the association between HYDIN mutations (HYDIN-MUT) in melanoma and ICIs efficacy.
METHODS
Clinical data and sequencing data from published studies were utilized to assess the association between HYDIN-MUT and the efficacy of ICIs treatment in melanoma patients.
RESULTS
Compared to other tumor types, HYDIN (36.14%) has the highest mutation rate in melanoma patients. In the anti-PD-1 treated cohort (n = 254), the HYDIN-MUT patients had a longer OS after ICIs treatment than the HYDIN wild-type (HYDIN-WT) patients (HR = 0.590 [95% CI, 0.410-0.847], P = 0.004); the objective response rate (ORR) and durable clinical benefit (DCB) were increased in patients with HYDIN-MUT (ORR = 46.25, DCB = 56.00%) compared to patients with HYDIN-WT (ORR = 30.99%, DCB = 42.76%) (ORR: P = 0.019; DCB: P = 0.060). In the anti-CTLA4 treated cohort (n = 174), HYDIN-MUT patients achieved significantly longer OS than HYDIN-WT patients (HR = 0.549 [95% CI, 0.366-0.823], P = 0.003); the proportion of ORR and DCB in HYDIN-MUT patients was significantly higher than that in HYDIN-WT patients (ORR 40.54% vs. 14.42%, P = 0.031; DCB 45.76% vs. 22.22%, P = 0.002). Further gene set enrichment analysis demonstrated that DNA repair and anti-tumor immunity were significantly enhanced in HYDIN-MUT patients.
CONCLUSIONS
HYDIN mutations are a potential predictive biomarker of ICIs efficacy in melanoma patients.
Identifiants
pubmed: 37595251
pii: 204925
doi: 10.18632/aging.204925
pmc: PMC10496993
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7997-8012Références
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Cancer Res. 1999 Oct 15;59(20):5059-63
pubmed: 10537273
J Mol Genet Med. 2015 Dec;9(4):
pubmed: 26870154
Radiother Oncol. 2022 Aug;173:299-305
pubmed: 35772575
Oncoimmunology. 2019 Jun 16;8(9):e1629258
pubmed: 31428527
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
J Immunother Cancer. 2019 Jul 12;7(1):180
pubmed: 31300034
Clin Cancer Res. 2017 Sep 1;23(17):5024-5033
pubmed: 28512174
J Clin Oncol. 2016 Mar 10;34(8):871-8
pubmed: 26811525
Nature. 2014 Nov 27;515(7528):577-81
pubmed: 25428507
Nat Rev Immunol. 2018 Mar;18(3):168-182
pubmed: 29226910
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Front Pharmacol. 2022 Aug 30;13:937874
pubmed: 36110546
Am J Pathol. 1996 Jun;148(6):1887-94
pubmed: 8669474
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Front Oncol. 2021 Jun 17;11:666145
pubmed: 34221982
BMC Biol. 2007 Aug 07;5:33
pubmed: 17683645
Ann Transl Med. 2019 Nov;7(22):648
pubmed: 31930049
Nat Med. 2019 Dec;25(12):1916-1927
pubmed: 31792460
Front Immunol. 2022 Aug 04;13:951137
pubmed: 35990657
Cancer Control. 2008 Jul;15(3):196-201
pubmed: 18596671
J Natl Cancer Inst. 2021 Feb 1;113(2):162-170
pubmed: 32294209
Cancer Cell. 2019 Feb 11;35(2):238-255.e6
pubmed: 30753825
Front Pharmacol. 2022 Sep 26;13:1018411
pubmed: 36225582
Cold Spring Harb Symp Quant Biol. 2000;65:127-33
pubmed: 12760027
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
J Cell Biol. 2008 Feb 11;180(3):633-43
pubmed: 18250199
Clin Plast Surg. 2021 Oct;48(4):543-550
pubmed: 34503715
Maturitas. 2001 Feb 28;38(1):17-22; discussion 22-3
pubmed: 11311581
Front Oncol. 2017 Sep 27;7:233
pubmed: 29034210
Eur J Cancer. 2018 Sep;101:236-243
pubmed: 30096704
Front Oncol. 2021 Mar 01;10:558760
pubmed: 33732635
Cancer Med. 2021 Jun;10(12):4004-4016
pubmed: 33982398
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
JAMA. 2023 Mar 21;329(11):948
pubmed: 36867424
Nat Med. 2022 Feb;28(2):353-362
pubmed: 35027754
Melanoma Res. 1997 Aug;7(4):313-21
pubmed: 9293481
Oncoimmunology. 2016 Mar 10;5(5):e1051299
pubmed: 27467925
Front Oncol. 2022 Jan 19;11:791912
pubmed: 35127498
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Hum Mol Genet. 2003 May 15;12(10):1163-70
pubmed: 12719380
Cancer Immunol Res. 2013 Sep;1(3):190-200
pubmed: 24777681
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
Curr Treat Options Oncol. 2019 Jan 24;20(1):7
pubmed: 30675668
Lancet Oncol. 2018 Mar;19(3):310-322
pubmed: 29449192
Ann Oncol. 2019 Sep 1;30(9):1479-1486
pubmed: 31236579
Pigment Cell Melanoma Res. 2021 Sep;34(5):978-983
pubmed: 33449414
Br J Cancer. 2017 Apr 25;116(9):1141-1147
pubmed: 28324889
BMC Gastroenterol. 2022 Mar 14;22(1):121
pubmed: 35287591
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Eur J Cancer. 2004 Aug;40(12):1825-36
pubmed: 15288283
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254